Breeze Holdings Acquisition Corp. Announces Definitive Agreement to Merge with YD Biopharma Limited

YD Biopharma is a Clinical-Stage Biopharmaceutical Company Focusing on Cancer Prevention Diagnostics and Seeking to Transform the Treatment of a Wide Spectrum of Diseases Pro Forma for the Transaction, Combined Company is Expected to Have an Estimated Enterprise Value of Nearly $700 Million The Proposed Merger is Expected to Close by Early 2025; After Closing, the Combined Company is Expected to be Listed on Nasdaq Capital Market YD Biopharma has Recently Obtained Patents, Technology, and U.S. Authorization ...